Indian Journal of Clinical Biochemistry

, Volume 26, Issue 1, pp 70–73 | Cite as

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

  • Vanita R. Jagtap
  • Jayashri V. Ganu
  • Nitin S. Nagane
Original Article


India seems to have the highest prevalence of osteoporosis. With growing awareness of osteoporosis and its impact on life span especially in India, special attention is being paid to early detection, management and treatment of postmenopausal osteoporosis in women. Measurement of BMD and osteocalcin are of value in estimating bone turnover rates. The aim of this study is (1) to measure the specific, sensitive bone formation marker such as osteocalcin and BMD in postmenopausal osteoporosis women and postmenopausal non-osteoporosis women; (2) the follow up study to evaluate the impact of specific antiresorptive therapy (alendronate + calcium + vitamin D) regimen in postmenopausal osteoporosis by assaying osteocalcin and BMD. Sixty clinically diagnosed postmenopausal osteoporosis patients and 60 normal subjects (postmenopausal non-osteoporosis women) were recruited as control. Mean bone mineral density T score and Z score was significantly decreased (P < 0.001) in postmenopausal osteoporosis patients as compared to controls. Highly significant increase in the mean score of BMD—T score and Z score from baseline to post therapy of 3 months was observed in postmenopausal osteoporosis women. Serum osteocalcin levels were significantly increased (P < 0.001) as compared to control group. Serum osteocalcin levels were decreased significantly (P < 0.001) from baseline to post therapy of 3 months in postmenopausal osteoporosis women. BMD is the best quantifiable predictor of osteoporotic fracture and osteocalcin is specific, sensitive, promising, currently used marker for better prognosis of osteoporosis and for monitoring responses to antiresorptive therapy.


Bone formation marker Bone mineral density Postmenopausal osteoporosis 


  1. 1.
    Axelrod DW, Teitelbaum SL. Results of long-term cyclical etidronate therapy: bone histomorphometry and clinical correlates. J Bone Miner Res. 1994;9S1:136.Google Scholar
  2. 2.
    Moyad MA. Preventing male osteoporosis: prevalence, risks, diagnosis and imaging tests. Urol Clin N Am. 2004;31:321–30.CrossRefGoogle Scholar
  3. 3.
    Neetakumar, Ammini AC, Tandon N, Goswami R, Dineshkumar, Singh A. Ethnic variation of host and risk factors in silent epidemic of osteoporosis. Orthoped Today. 2004;VI(4):240–4.Google Scholar
  4. 4.
    Sachdeva A, Seth S, Khosla AH, Sachdeva S. Study of some common biochemical bone turnover markers in postmenopausal women. Ind J Clin Biochem. 2005;20(1):131–4.CrossRefGoogle Scholar
  5. 5.
    Dogan E, Posaci C. Monitoring hormone replacement therapy by biochemical marker of bone metabolism in menopausal women. Post Graduate Med J. 2002;78:727–31.CrossRefGoogle Scholar
  6. 6.
    Bauer DC, Gluer CC, Cauley JA. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. Arch Int Med. 1997;157:629–34.CrossRefGoogle Scholar
  7. 7.
    Brown JP, Delmas PD. Serum BGP a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984;i:1091–3.CrossRefGoogle Scholar
  8. 8.
    Johannes WG, Pet PMM, Ron NJ, Lems WF, Roland FJ, Ann MH, Ale A, Erik B, Lorenz CH, George AWB, Ben ACD. Prevention of glucocorticoid induced osteoporosis with alendronate or alfa calcidiol: relations of change in bone mineral density, bone markers and calcium homeostasis. J Rheumatol. 2007;34:1051–7.Google Scholar
  9. 9.
    Ones K, Schacht E, Dukas L, Caglar N. Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two years, randomized, multiarm, controlled trial. Int J Epidemiol. 2007;4(4):1–9.Google Scholar
  10. 10.
    Rhee Y, Kang M, Min Y, Byun D, Chung Y, Ahn C, Back K, Mok J, Kim D, Kim H, Myoung S, Kim Y, Lim SK. Effects of combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double—blind, randomized, placebo-controlled study. Osteoporos Int. 2006;17(12):1801–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Power MJ, Fottrell PF. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci. 1991;28:287–335.CrossRefPubMedGoogle Scholar
  12. 12.
    Pino JD, Gomez EM, Rodriguez MM, Sosa CL, Cordero M, Lanchares JL, Talavera JRG. Influence of sex, age and menopause in serum osteocalcin (BGP) levels. J Mol Med. 1991;69(24):1135–8.Google Scholar
  13. 13.
    Verit FF, Yazgan P, Geyikli C, Zer Y, Celik A. Diagnostic value of TRAP 5b activity in postmenopausal osteoporosis. J Turkish-German Gynecol Assoc. 2006;7(2):120–4.Google Scholar
  14. 14.
    Cabrera CD, Henriquez MS, Traba ML, Villafane EA, Piedra DL. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporos Int. 1998;8(2):147–51.CrossRefGoogle Scholar
  15. 15.
    Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem. 1995;41(10):1439–45.PubMedGoogle Scholar
  16. 16.
    Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson -Briffa KN, Eisman A, Nicholson GC. Prevention and treatment of glucocoriticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res. 2003;18(5):919–24.CrossRefPubMedGoogle Scholar
  17. 17.
    Fardellone P, Brazier M, Kamel S, Gueris J, Graulet AM, Lienard J, Sebert JL. Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake. Am J Clin Nutr. 1998;67:1273–8.PubMedGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2010

Authors and Affiliations

  • Vanita R. Jagtap
    • 1
  • Jayashri V. Ganu
    • 1
  • Nitin S. Nagane
    • 1
  1. 1.Department of BiochemistryGovernment Medical CollegeMirajIndia

Personalised recommendations